Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering

G Niccoli, JA Borovac, Vincenzo Vetrugno, PG Camici, Filippo Crea

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Ivabradine is a heart rate reducing agent that exhibits anti-ischemic effects through the inhibition of funny electrical current in the sinus node resulting in heart rate reduction, thus enabling longer diastolic perfusion time, and reduced myocardial oxygen consumption without detrimental changes in arterial blood pressure, coronary vasomotion, and ventricular contractility. The current guideline-based clinical use of Ivabradine is reserved for patients with stable angina pectoris who cannot tolerate or whose symptoms are inadequately controlled with beta blockers. In patients with chronic heart failure and reduced ejection fraction, Ivabradine has demonstrated beneficial effects in improving clinical outcomes when added to conventional therapy. However, the role of Ivabradine in acute coronary syndromes has not been established. Based on the results from some relevant preclinical studies and a limited amount of clinical data that were reported recently, the role of Ivabradine in acute ischemic events warrants further investigation. The aim of this review is to provide an overview of the available literature on the potential role of Ivabradine in the clinical context of acute coronary syndromes. © 2017 Elsevier B.V.
Original languageEnglish
Pages (from-to)107-112
Number of pages6
JournalInternational Journal of Cardiology
Volume236
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

ivabradine
Acute Coronary Syndrome
Heart Rate
Sinoatrial Node
Stable Angina
Reducing Agents
Oxygen Consumption
Arterial Pressure
Heart Failure
Perfusion
Guidelines

Cite this

Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering. / Niccoli, G; Borovac, JA; Vetrugno, Vincenzo; Camici, PG; Crea, Filippo.

In: International Journal of Cardiology, Vol. 236, No. 3, 2017, p. 107-112.

Research output: Contribution to journalArticle

Niccoli, G ; Borovac, JA ; Vetrugno, Vincenzo ; Camici, PG ; Crea, Filippo. / Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering. In: International Journal of Cardiology. 2017 ; Vol. 236, No. 3. pp. 107-112.
@article{c5d0bfbd313c4251a62d81aee5da7f2b,
title = "Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering",
abstract = "Ivabradine is a heart rate reducing agent that exhibits anti-ischemic effects through the inhibition of funny electrical current in the sinus node resulting in heart rate reduction, thus enabling longer diastolic perfusion time, and reduced myocardial oxygen consumption without detrimental changes in arterial blood pressure, coronary vasomotion, and ventricular contractility. The current guideline-based clinical use of Ivabradine is reserved for patients with stable angina pectoris who cannot tolerate or whose symptoms are inadequately controlled with beta blockers. In patients with chronic heart failure and reduced ejection fraction, Ivabradine has demonstrated beneficial effects in improving clinical outcomes when added to conventional therapy. However, the role of Ivabradine in acute coronary syndromes has not been established. Based on the results from some relevant preclinical studies and a limited amount of clinical data that were reported recently, the role of Ivabradine in acute ischemic events warrants further investigation. The aim of this review is to provide an overview of the available literature on the potential role of Ivabradine in the clinical context of acute coronary syndromes. {\circledC} 2017 Elsevier B.V.",
author = "G Niccoli and JA Borovac and Vincenzo Vetrugno and PG Camici and Filippo Crea",
year = "2017",
doi = "10.1016/j.ijcard.2017.02.046",
language = "English",
volume = "236",
pages = "107--112",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering

AU - Niccoli, G

AU - Borovac, JA

AU - Vetrugno, Vincenzo

AU - Camici, PG

AU - Crea, Filippo

PY - 2017

Y1 - 2017

N2 - Ivabradine is a heart rate reducing agent that exhibits anti-ischemic effects through the inhibition of funny electrical current in the sinus node resulting in heart rate reduction, thus enabling longer diastolic perfusion time, and reduced myocardial oxygen consumption without detrimental changes in arterial blood pressure, coronary vasomotion, and ventricular contractility. The current guideline-based clinical use of Ivabradine is reserved for patients with stable angina pectoris who cannot tolerate or whose symptoms are inadequately controlled with beta blockers. In patients with chronic heart failure and reduced ejection fraction, Ivabradine has demonstrated beneficial effects in improving clinical outcomes when added to conventional therapy. However, the role of Ivabradine in acute coronary syndromes has not been established. Based on the results from some relevant preclinical studies and a limited amount of clinical data that were reported recently, the role of Ivabradine in acute ischemic events warrants further investigation. The aim of this review is to provide an overview of the available literature on the potential role of Ivabradine in the clinical context of acute coronary syndromes. © 2017 Elsevier B.V.

AB - Ivabradine is a heart rate reducing agent that exhibits anti-ischemic effects through the inhibition of funny electrical current in the sinus node resulting in heart rate reduction, thus enabling longer diastolic perfusion time, and reduced myocardial oxygen consumption without detrimental changes in arterial blood pressure, coronary vasomotion, and ventricular contractility. The current guideline-based clinical use of Ivabradine is reserved for patients with stable angina pectoris who cannot tolerate or whose symptoms are inadequately controlled with beta blockers. In patients with chronic heart failure and reduced ejection fraction, Ivabradine has demonstrated beneficial effects in improving clinical outcomes when added to conventional therapy. However, the role of Ivabradine in acute coronary syndromes has not been established. Based on the results from some relevant preclinical studies and a limited amount of clinical data that were reported recently, the role of Ivabradine in acute ischemic events warrants further investigation. The aim of this review is to provide an overview of the available literature on the potential role of Ivabradine in the clinical context of acute coronary syndromes. © 2017 Elsevier B.V.

U2 - 10.1016/j.ijcard.2017.02.046

DO - 10.1016/j.ijcard.2017.02.046

M3 - Article

VL - 236

SP - 107

EP - 112

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -